2019
1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D
DANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D. Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.Peer-Reviewed Original ResearchOptimized insulin therapyInsulin therapySpouse/partnerSanofi USDiabetes careDohme Corp.Novo Nordisk A/SSanofi-AventisEli LillyMerck SharpAdvisory PanelPhase 3 studyLexicon PharmaceuticalsOptimal glycemic controlRisk of hypoglycemiaLevel 2 hypoglycemiaLower ratesAmgen Inc.Boehringer Ingelheim PharmaceuticalsDual SGLT1Important hypoglycemiaMannKind CorporationPatient yearsWeek 52Glycemic control
2018
Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D
PETTUS J, WEINZIMER S, MCCRIMMON R, AMPUDIA BLASCO F, STEWART J, STRUMPH P, OLIVEIRA J, LAPUERTA P, CASTRO R. Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D. Diabetes 2018, 67 DOI: 10.2337/db18-5-lb.Peer-Reviewed Original ResearchInsulin dose changesDaily insulin doseTotal daily insulin doseOptimized insulin therapyInsulin doseInsulin therapySevere hypoBolus insulinGlycemic controlLexicon PharmaceuticalsMycotic infectionsDose changesTreatment-emergent adverse eventsInsulin reductionLS meanDaily insulin requirementGenital mycotic infectionsSanofi-AventisAdequate glycemic controlGood glycemic controlBody mass indexRisk of hypoglycemiaRenal glucose reabsorptionNumber of patientsType of insulin